Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

CUREMAL · Innovative Transformative CURE for MALaria: Rapid-Action Combinations to Replace Artemisinins

HORIZONStatus: SIGNED1 June 202630 November 2030EU funding €8,417,294Call HORIZON-JU-GH-EDCTP3-2025-01-two-stage

CUREMAL project aims to address the urgent need for new malaria treatments due to the increasing resistance to current therapies. Malaria remains a significant global health challenge, particularly in sub-Saharan Africa, where it causes the majority of malaria-related deaths. The project focuses on developing GSK701, a novel antimalarial compound with a unique mechanism of action, showing no cross-resistance with existing drugs and potential for a single-dose cure.The partners will conduct two clinical trials to evaluate the safety, efficacy, and pharmacokinetics of GSK701 in combination with pyronaridine. These trials will be carried out in malaria-endemic regions from Gabon, Tanzania, Uganda and Mozambique, targeting vulnerable populations, including children and adolescents. The trials will also involve detailed molecular surveillance to understand the effectiveness of the new treatment and monitor resistance patterns.Key objectives include assessing the safety and tolerability of various dosing regimens, evaluating the pharmacokinetic/pharmacodynamic relationship, and identifying genetic variants associated with resistance. The project will also focus on building capacity in African research centres for conducting clinical trials and genetic surveillance. The expected outcomes include progressing GSK701 through development stages, enhancing molecular surveillance of antimalarial resistance, and fostering global and intra-African collaborations. The project aims to contribute to malaria control and elimination efforts, improve treatment adherence with simplified regimens, and support the achievement of the 2030 Sustainable Development Goals related to health.By leveraging multidisciplinary expertise, cutting-edge technology and partners´ in-kind resources, CUREMAL seeks to make a significant impact on public health, providing a robust solution to the growing challenge of antimalarial resistance and advancing towards the ultimate goal of malaria eradication.

Consortium · 11 organisations

coordinator

GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL

ES

thirdParty

GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

UK

participant

FUNDACAO MANHICA

MZ · €390,254

participant

FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA

ES · €1,409,688

participant

THE REGISTERED TRUSTEES OF THE IFAKARA HEALTH INSTITUTE

TZ · €1,569,232

participant

MMV MEDICINES FOR MALARIA VENTURE

CH

participant

INFECTIOUS DISEASES RESEARCH COLLABORATION LTD BY GUARANTEE

UG · €1,689,435

thirdParty

HOSPITAL CLINIC DE BARCELONA

ES

participant

EBERHARD KARLS UNIVERSITAET TUEBINGEN

DE · €207,295

participant

Centre de Recherches Medicales de Lambaréné

GA · €2,008,650

participant

STELLENBOSCH UNIVERSITY

ZA · €1,142,741

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.